DOI : 10.1055/s-00034924

Nuklearmedizin - NuclearMedicine

Ausgabe 02 · Volume 60 · April 2021 DOI: 10.1055/s-011-50684

Deutsche Gesellschaft für Nuklearmedizin
NuklearMedizin 2021 – digital
, 14.-17.04.2021

Prof. Dr. Michael Schäfers
Abstracts (HTML) Abstracts (PDF) Autorenliste
L9
Schmidkonz, C; Rauber, S; Atzinger, A; Götz, TI; Soare, A; Cordes, M; Prante, O; Ritt, P; Bäuerle, T; Köhner, M; Haberkorn, U; Kuwert, T; Schett, G; Ramming, A: Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
L10
Backhaus, P; Burg, MC; Roll, W; Büther, F; Breyholz, HJ; Weigel, SB; Heindel, W; Pixberg, M; Barth, P; Tio, J; Schäfers, M: A new horizon for breast cancer staging: first evidence from simultaneous PET-MRI targeting the fibroblast activating protein (FAP)
L11
Rullmann, M; Brendel, M; Schroeter, ML; Saur, D; Levin, J; Perneczky, R; Tiepolt, S; Patt, M; Mueller, A; Villemagne, VL; Classen, J; Stephens, AW; Sabri, O; Barthel, H: Multicenter F-18-PI-2620 PET for in vivo Braak staging of tau pathology in Alzheimer’s disease
L12
Rauscher, I; Karimzadeh, A; Schiller, K; Horn, T; Weber, WA; Eiber, M: Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment
L13
Bergmann, R; Arndt, C; Máthé, D; Berndt, N; Loureiro, LR; Kovács, N; Szöllösi, D; Hegedüs, N; Kovács, T; Kopka, K; Bachmann, M; Feldmann, A: Copper-64/Actinium-225-human anti-PSCA-IgG4 theranostics of a prostate cancer model
L14
Miller, K; Higano, C; Saad, F; Sartor, O; Conti, P; George, D; Sternberg, CN; Shore, N; Sade, JP; Bellmunt, J; Smith, M; Logothetis, C; Verholen, F; Kalinovsky, J; Bayh, I; Tombal, B: Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
L15
Rottenburger, C; Nicolas, G; McDougall, L; Fürstner, M; Hentschel, M; Kaul, F; Christ, ER; Cachovan, M; Vija, HA; Schibli, R; Geistlich, S; Béhé, M; Wild, D: The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study
L16
Beyer, L; Gosewisch, A; Lindner, S; Völter, F; Mittlmeier, LM; Tiling, R; Cyran, CC; Unterrainer, M; Rübenthaler, J; Auernhammer, CJ; Spitzweg, C; Böning, G; Gildehaus, FJ; Jurkschaft, K; Wängler, C; Waengler, B; Schirrmacher, R; Todica, A; Bartenstein, P; Ilhan, H: Dosimetry and optimal time frame of [18F]SiTATE PET/CT in Patients with Neuroendocrine Carcinoma